Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Product Type
  5. Dna Rna Therapeutics

DNA & RNA Therapeutics

Evaluate

Thumbnail
May 18, 2023

Orbital shows 2023’s venture funding scene is far from stratospheric

The group’s $270m series A, big for 2023, is not that impressive compared with other years.

Thumbnail
April 26, 2023

Arrowhead delivers in the lung

Early clinical data with an inhaled RNA interference candidate look promising, but there is still much to prove.

Article image
Vantage logo
April 16, 2023

AACR 2023 – more hope for Moderna’s neoantigen immunotherapy

After Moderna/Merck & Co’s December splash, full data from Keynote-942 stand up to scrutiny.

Article image
Vantage logo
March 24, 2023

Spotlight – Vertex flexes its dealmaking muscle

The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.

Article image
Vantage logo
February 24, 2023

Spotlight – Cystic fibrosis developers take a deep breath

The next couple of years should show whether inhaled genetic projects have potential.

Article image
Vantage logo
February 17, 2023

Moderna’s post-Covid prospects dim

Article image
Vantage logo
February 08, 2023

Arrowhead's hep B plans in jeopardy

Article image
Vantage logo
December 08, 2022

Vertex taps Entrada for another try at myotonic dystrophy

Article image
Vantage logo
November 07, 2022

Ionis gets a double whammy

Article image
Vantage logo
November 02, 2022

CSL stops short of buying Arcturus

Article image
Vantage logo
October 14, 2022

Cancer “vaccines” enter the neoantigen stage

Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up